Last reviewed · How we verify
Hemay181
At a glance
| Generic name | Hemay181 |
|---|---|
| Sponsor | Ganzhou Hemay Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 (PHASE1)
- A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemay181 CI brief — competitive landscape report
- Hemay181 updates RSS · CI watch RSS
- Ganzhou Hemay Pharmaceutical Co., Ltd portfolio CI